Hyodeoxycholylglycine | 13042-33-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Hyodeoxycholylglycine
• 英文别名: 2-[4-(3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]acetic acid
• CAS: 13042-33-6
• 化学式: C₂₆H₄₃NO₅
• 分子量: 449.6
• InChiKey: SPOIYSFQOFYOFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  655.6±40.0 °C(Predicted)
• 密度：
  1.162±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：30 mg/ml； DMF:PBS(pH 7.2)(1:1)：0.5 mg/ml； DMSO：20 mg/ml；乙醇：20 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  5

制备方法与用途

生物活性

Glycohyodeoxycholic acid 是人体内 Hyodeoxycholic acid 的主要代谢产物，对胆结石的形成具有预防作用。

靶点

Human Endogenous Metabolite

文献信息

• DIHYDROARTEMISININ-STEROID CONJUGATE AND PREPARATION METHOD AND USE THEREOF
  申请人：Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd.

  公开号：EP3617218A1

  公开（公告）日：2020-03-04

  Described is a dihydroartemisinin-steroid conjugate of formula (I), or a pharmaceutically acceptable salt thereof, where position 10 of dihydroartemisinin is linked to the steroid through a linker X. This application further provides a preparation method of the dihydroartemisinin-steroid conjugate and an application of the dihydroartemisinin-steroid conjugate in the preparation of a drug for treating cancer. The dihydroartemisinin-steroid conjugate of the invention exhibits potent inhibitory activity against various tumor cells and low cytotoxicity, moreover, the conjugate is capable of penetrating the blood-brain barrier, having a broad application prospect.

  本申请进一步提供了双氢青蒿素-类固醇共轭物的制备方法以及双氢青蒿素-类固醇共轭物在制备治疗癌症药物中的应用。本发明的双氢青蒿素-类固醇共轭物对多种肿瘤细胞具有强效抑制活性，细胞毒性低，而且共轭物能够穿透血脑屏障，具有广阔的应用前景。
• BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF
  申请人：Shenzhen Yunhe Pharmaceutical Technology Partnership (Limited)

  公开号：EP4019528A1

  公开（公告）日：2022-06-29

  Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TGR5. The bile acid derivative of the present invention inhibits or delays the metabolism of bile acid by bacterial BSH/7α dehydroxylase in the intestine and greatly prolongs the effective survival time of bile acid in the intestine. The bile acid derivative and the pharmaceutical composition thereof can significantly stimulate bile acid membrane receptor TGR5, promote the secretion of glucagon-like peptide 1 from enteroendocrine cells, reduce liver fat accumulation, significantly improve liver function and increase glucose tolerance, thereby having an excellent effect on the treatment of fatty liver disease.

  本发明提供了一种用于治疗脂肪肝的新型胆汁酸衍生物、其药物组合物以及在制备治疗和改善由FXR或TGR5介导或引起的疾病和症状的药物中的用途。本发明的胆汁酸衍生物可抑制或延缓胆汁酸在肠道中被细菌BSH/7α脱羟化酶代谢，大大延长胆汁酸在肠道中的有效存活时间。该胆汁酸衍生物及其药物组合物能显著刺激胆汁酸膜受体TGR5，促进肠内分泌细胞分泌胰高血糖素样肽1，减少肝脏脂肪堆积，明显改善肝功能，提高糖耐量，从而对脂肪肝的治疗有很好的效果。
• Bile acid receptor agonism for treating addiction
  申请人：Vanderbilt University

  公开号：US10064876B2

  公开（公告）日：2018-09-04

  Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.

  本发明公开了用于治疗受试者成瘾的组合物和方法。特别是，公开了治疗多巴胺能精神兴奋剂成瘾的组合物和方法。在一些实施方案中，通过激动受试者体内的胆汁酸受体来治疗成瘾。例如，在一些实施方案中，该方法包括向受试者施用治疗有效量的组合物，该组合物包含治疗有效量的胆汁酸受体激动剂。在一些实施方案中，该方法包括以适合增加受试者体内循环胆汁酸的方式，通过手术转移受试者体内的胆汁酸。
• Biomarkers related to organ function
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10634686B2

  公开（公告）日：2020-04-28

  Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.

  本文公开了鉴定可用于预测器官或组织功能或功能障碍的生物标记物（如基因（如 RNA 或 mRNA）、蛋白质和/或小分子）的方法。在一些实施方案中，这些方法包括对器官或组织进行体外灌注，收集器官或组织的样本（例如灌注液、器官产生的液体（如胆汁或尿液）或组织活检），并测量样本中一种或多种生物标记物的水平。本文还公开了对来自器官、组织或受试者的生物样本中存在的生物标记物（如基因（如 RNA 或 mRNA）、蛋白质和/或小分子）的分析，可用于确定器官、组织或受试者是否有器官功能障碍或器官衰竭的风险（或已出现器官功能障碍或器官衰竭）。
• Dihydroartemisinin-steroid conjugate and preparation method and application thereof
  申请人：YUNBAIYAO ZHENGWU SCIENCE AND TECHNOLOGY (SHANGHAI) CO., LTD.

  公开号：US10881636B2

  公开（公告）日：2021-01-05

  Described is a dihydroartemisinin-steroid conjugate of formula (I), or a pharmaceutically acceptable salt thereof, where position 10 of dihydroartemisinin is linked to the steroid through a linker X. This application further provides a preparation method of the dihydroartemisinin-steroid conjugate and an application of the dihydroartemisinin-steroid conjugate in the preparation of a drug for treating cancer. The dihydroartemisinin-steroid conjugate of the invention exhibits potent inhibitory activity against various tumor cells and low cytotoxicity, moreover, the conjugate is capable of penetrating the blood-brain barrier, having a broad application prospect.

  本申请进一步提供了双氢青蒿素-类固醇共轭物的制备方法以及双氢青蒿素-类固醇共轭物在制备治疗癌症药物中的应用。 本发明的双氢青蒿素-类固醇共轭物对多种肿瘤细胞具有强效抑制活性，细胞毒性低，而且共轭物能够穿透血脑屏障，具有广阔的应用前景。